CLINICAL_TRIALS
trial_result
· 2015-04-21
Clinical Trial Update: Assessment of V0018 1.5 mg Effect on Craving [Phase 2]
Summary
Phase 2 trial evaluating V0018 1.5 mg for craving reduction in tobacco use disorder; the study has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pierre Fabre Medicament | Conditions: Smoking | Phase 2 | Status: COMPLETED